Cargando…
Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Ful...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274940/ https://www.ncbi.nlm.nih.gov/pubmed/35292607 http://dx.doi.org/10.1159/000524087 |
_version_ | 1784745392884154368 |
---|---|
author | Milojević, Ana Zdravković, Marija Brajković, Milica Memon, Lidija Gardijan, Vera Vekić, Jelena Zeljković, Aleksandra Stefanović, Aleksandra Mihajlović, Marija Ivanišević, Jasmina Bogavac-Stanojević, Nataša Radosavljević, Vojislav Spasojević-Kalimanovska, Vesna Ninić, Ana |
author_facet | Milojević, Ana Zdravković, Marija Brajković, Milica Memon, Lidija Gardijan, Vera Vekić, Jelena Zeljković, Aleksandra Stefanović, Aleksandra Mihajlović, Marija Ivanišević, Jasmina Bogavac-Stanojević, Nataša Radosavljević, Vojislav Spasojević-Kalimanovska, Vesna Ninić, Ana |
author_sort | Milojević, Ana |
collection | PubMed |
description | OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. RESULTS: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m<sup>2</sup>) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m<sup>2</sup> when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). CONCLUSION: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9. |
format | Online Article Text |
id | pubmed-9274940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-92749402022-08-16 Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea Milojević, Ana Zdravković, Marija Brajković, Milica Memon, Lidija Gardijan, Vera Vekić, Jelena Zeljković, Aleksandra Stefanović, Aleksandra Mihajlović, Marija Ivanišević, Jasmina Bogavac-Stanojević, Nataša Radosavljević, Vojislav Spasojević-Kalimanovska, Vesna Ninić, Ana Med Princ Pract Original Paper OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. RESULTS: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m<sup>2</sup>) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m<sup>2</sup> when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). CONCLUSION: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9. S. Karger AG 2022-03-15 /pmc/articles/PMC9274940/ /pubmed/35292607 http://dx.doi.org/10.1159/000524087 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Original Paper Milojević, Ana Zdravković, Marija Brajković, Milica Memon, Lidija Gardijan, Vera Vekić, Jelena Zeljković, Aleksandra Stefanović, Aleksandra Mihajlović, Marija Ivanišević, Jasmina Bogavac-Stanojević, Nataša Radosavljević, Vojislav Spasojević-Kalimanovska, Vesna Ninić, Ana Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title_full | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title_fullStr | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title_full_unstemmed | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title_short | Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea |
title_sort | effects of apnea, obesity, and statin therapy on proprotein convertase subtilisin/kexin 9 levels in patients with obstructive sleep apnea |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274940/ https://www.ncbi.nlm.nih.gov/pubmed/35292607 http://dx.doi.org/10.1159/000524087 |
work_keys_str_mv | AT milojevicana effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT zdravkovicmarija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT brajkovicmilica effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT memonlidija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT gardijanvera effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT vekicjelena effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT zeljkovicaleksandra effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT stefanovicaleksandra effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT mihajlovicmarija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT ivanisevicjasmina effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT bogavacstanojevicnatasa effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT radosavljevicvojislav effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT spasojevickalimanovskavesna effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea AT ninicana effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea |